Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. More Details
Good value with acceptable track record.
Share Price & News
How has Integra LifeSciences Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IART is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: IART's weekly volatility (3%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: IART exceeded the US Medical Equipment industry which returned 29.9% over the past year.
Return vs Market: IART exceeded the US Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Integra LifeSciences Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShould You Think About Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART) Now?
3 weeks ago | Simply Wall StDid Integra LifeSciences Holdings' (NASDAQ:IART) Share Price Deserve to Gain 70%?
1 month ago | Simply Wall StIs Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 28% Discount?
Is Integra LifeSciences Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IART ($72.39) is trading below our estimate of fair value ($107.22)
Significantly Below Fair Value: IART is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IART is good value based on its PE Ratio (29.7x) compared to the US Medical Equipment industry average (49x).
PE vs Market: IART is poor value based on its PE Ratio (29.7x) compared to the US market (18.1x).
Price to Earnings Growth Ratio
PEG Ratio: IART is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: IART is good value based on its PB Ratio (3.9x) compared to the US Medical Equipment industry average (4.5x).
How is Integra LifeSciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IART's forecast earnings growth (15.4% per year) is above the savings rate (2%).
Earnings vs Market: IART's earnings (15.4% per year) are forecast to grow faster than the US market (15% per year).
High Growth Earnings: IART's earnings are forecast to grow, but not significantly.
Revenue vs Market: IART's revenue (6.3% per year) is forecast to grow slower than the US market (9.2% per year).
High Growth Revenue: IART's revenue (6.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IART's Return on Equity is forecast to be low in 3 years time (14.4%).
How has Integra LifeSciences Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IART has high quality earnings.
Growing Profit Margin: IART became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: IART's earnings have grown by 19.5% per year over the past 5 years.
Accelerating Growth: IART has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: IART has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (30.1%).
Return on Equity
High ROE: IART's Return on Equity (13.1%) is considered low.
How is Integra LifeSciences Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IART's short term assets ($1.0B) exceed its short term liabilities ($318.8M).
Long Term Liabilities: IART's short term assets ($1.0B) do not cover its long term liabilities ($1.8B).
Debt to Equity History and Analysis
Debt Level: IART's debt to equity ratio (102.3%) is considered high.
Reducing Debt: IART's debt to equity ratio has increased from 88.8% to 102.3% over the past 5 years.
Debt Coverage: IART's debt is not well covered by operating cash flow (19.3%).
Interest Coverage: IART's interest payments on its debt are well covered by EBIT (5x coverage).
What is Integra LifeSciences Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IART's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IART's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IART's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IART's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IART's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pete Arduini (56 yo)
Mr. Peter J. Arduini, also known as Pete, has been the Chief Executive Officer of Integra LifeSciences Holdings Corporation (formerly, Integra LifeSciences Corporation) since January 3, 2012 and has been i...
CEO Compensation Analysis
Compensation vs Market: Pete's total compensation ($USD7.74M) is about average for companies of similar size in the US market ($USD6.51M).
Compensation vs Earnings: Pete's compensation has been consistent with company performance over the past year.
Experienced Management: IART's management team is considered experienced (3.8 years average tenure).
Experienced Board: IART's board of directors are considered experienced (8.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IART insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Integra LifeSciences Holdings Corporation's company bio, employee growth, exchange listings and data sources
- Name: Integra LifeSciences Holdings Corporation
- Ticker: IART
- Exchange: NasdaqGS
- Founded: 1989
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$6.123b
- Shares outstanding: 84.58m
- Website: https://www.integralife.com
Number of Employees
- Integra LifeSciences Holdings Corporation
- 1100 Campus Road
- New Jersey
- United States
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/01 22:13|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.